NCT02567149

Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Minnesota · Academic / Other
• Sex: All
• Age: 12 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to determine whether intralesional cidofovir is effective at bringing about the total or near-total resolution of warts that have already proven recalcitrant to standard therapy. The secondary objective is to determine the tolerability of this new mode of administration of cidofovir in the pediatric population

Detailed description

This study includes pediatric patients with history of either primary or iatrogenic immune-suppression who are seeking treatment of warts that have already proven recalcitrant to standard therapy. The first cohort will include 4 patients ages 12 to 17. After all tests indicate treatment safety, the second cohort will be recruited and will include patients ages 8 to 17.

Conditions

• Warts

Interventions

Type	Name	Description
DRUG	Cidofovir	Cidofovir

Timeline

• Start date: 2016-06-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2015-10-02
• Last updated: 2017-07-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study